{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:05:24Z","timestamp":1788527124141,"version":"build-2803163510"},"reference-count":39,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage. This multicenter, phase 2 trial evaluated the efficacy and safety of weekly oral pomalidomide-cyclophosphamide-dexamethasone (PCD) in patients with MM in first relapse after treatment with lenalidomide-bortezomib-dexamethasone (RVD). All patients had received RVD as induction and consolidation therapy, plus lenalidomide maintenance for 1 year (arm A). Half had also received an ASCT after induction (arm B). At MM relapse, all patients received 4 oral cycles of pomalidomide 4 mg (days 1-21), cyclophosphamide 300 mg (days 1, 8, 15, and 22), and dexamethasone 40 mg (days 1-4 and days 15-18 of a 28-day cycle; PCD). Responding patients in arm A underwent ASCT and received 2 additional cycles of PCD, whereas those in arm B received 5 cycles of PCD. All patients received pomalidomide-dexamethasone maintenance until disease progression. Primary end point was partial remission or better after the initial 4 cycles of PCD. Responses were obtained in 82\/97 (85%) patients evaluated: complete remission (n = 1; 1%), very good partial remission (n = 32; 33%), and partial remission (n = 49; 51%). Three patients (3%) had stable disease, and 6 (6%) had disease progression (6 response failures). Forty-five (94%) of the 48 patients in arm A underwent planned ASCT. PCD was effective therapy after first relapse with RVD. After 4 cycles, the rate of partial remission or better was 85%, and 94% of planned ASCTs were performed. Toxicity was mostly hematologic and manageable. This trial was registered at www.clinicaltrials.gov as #NCT02244125.<\/jats:p>","DOI":"10.1182\/blood-2018-07-863829","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T20:05:45Z","timestamp":1538597145000},"page":"2555-2563","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma"],"prefix":"10.1182","volume":"132","author":[{"given":"Laurent","family":"Garderet","sequence":"first","affiliation":[{"name":"Proliferation and Differentiation of Stem Cells, INSERM, Unit\u00e9 Mixte de Recherche (UMR)_S 938, Paris, France;"},{"name":"D\u00e9partement d'H\u00e9matologie et de Th\u00e9rapie Cellulaire, Assistance Publique des H\u00f4pitaux de Paris, H\u00f4pital Saint Antoine, Paris, France;"},{"name":"Sorbonne Universit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Kuhnowski","sequence":"first","affiliation":[{"name":"Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Berge","sequence":"first","affiliation":[{"name":"Euraxi, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-9428","authenticated-orcid":false,"given":"Murielle","family":"Roussel","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse\u2013Oncopole, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre-Barbe","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lafon","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"first","affiliation":[{"name":"Maladies du Sang, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"first","affiliation":[{"name":"Maladies du Sang, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Pierre Benite Cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Vandoeuvre Les Nancy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire H\u00f4tel Dieu, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Marit","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Stoppa","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Chaleteix","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Clermont Ferrand, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tiab","sequence":"first","affiliation":[{"name":"Hopital de La Roche sur Yon, La Roche sur Yon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Araujo","sequence":"first","affiliation":[{"name":"Centre Hospitalier de la C\u00f4te Basque, Bayonne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lenain","sequence":"first","affiliation":[{"name":"Centre Henri Becquerel, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Voog","sequence":"first","affiliation":[{"name":"Centre Hospitalier de Le Mans, Le Mans, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lofti","family":"Benboubker","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, H\u00f4pital Bretonneau, Tours, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Allangba","sequence":"first","affiliation":[{"name":"Centre Hospitalier de Saint Brieuc, Saint Brieuc, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jourdan","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, N\u00eemes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Orsini-Piocelle","sequence":"first","affiliation":[{"name":"Centre Hospitalier de la r\u00e9gion d\u2019Annecy, Pringy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Brechignac","sequence":"first","affiliation":[{"name":"H\u00f4pital Avicenne, Bobigny, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Richard","family":"Eveillard","sequence":"first","affiliation":[{"name":"H\u00f4pital Morvan, Brest, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Wetterwald","sequence":"first","affiliation":[{"name":"Centre Hospitalier G\u00e9n\u00e9ral, Dunkerque, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pegourie","sequence":"first","affiliation":[{"name":"Centre Hospitalier R\u00e9gional et Universitaire, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Eisenmann","sequence":"first","affiliation":[{"name":"H\u00f4pital Emile Muller, Mulhouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Glaisner","sequence":"first","affiliation":[{"name":"H\u00f4pital Ren\u00e9 Huguenin, Saint Cloud, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"Proliferation and Differentiation of Stem Cells, INSERM, Unit\u00e9 Mixte de Recherche (UMR)_S 938, Paris, France;"},{"name":"D\u00e9partement d'H\u00e9matologie et de Th\u00e9rapie Cellulaire, Assistance Publique des H\u00f4pitaux de Paris, H\u00f4pital Saint Antoine, Paris, France;"},{"name":"Sorbonne Universit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve Avet","family":"Loiseau","sequence":"first","affiliation":[{"name":"H\u00f4pital Rangueil, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mathiot","sequence":"first","affiliation":[{"name":"Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse\u2013Oncopole, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2020071008503194500_B1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2020071008503194500_B2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2020071008503194500_B3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2020071008503194500_B4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2020071008503194500_B5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2020071008503194500_B6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2020071008503194500_B7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2020071008503194500_B8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020071008503194500_B9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2020071008503194500_B10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"2020071008503194500_B11","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2020071008503194500_B12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020071008503194500_B13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"16","key":"2020071008503194500_B14","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2020071008503194500_B15","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2020071008503194500_B16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2020071008503194500_B17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma [published correction appears in Leukemia. 2007;21(5):1134; Leukemia. 2006;20(12):2220]","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"2020071008503194500_B18","article-title":"Common terminology criteria for adverse events. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 1 March 2018","author":"Cancer Therapy Evaluation Program"},{"issue":"1","key":"2020071008503194500_B19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"issue":"6","key":"2020071008503194500_B20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat Med"},{"issue":"19","key":"2020071008503194500_B21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"10068","key":"2020071008503194500_B22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"2020071008503194500_B23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020071008503194500_B24","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020071008503194500_B25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"issue":"6","key":"2020071008503194500_B26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"2020071008503194500_B27","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res"},{"issue":"12","key":"2020071008503194500_B28","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2020071008503194500_B29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1517\/13543784.2011.567265","article-title":"Pomalidomide therapy for myeloma","volume":"20","author":"Schey","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"2020071008503194500_B30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020071008503194500_B31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020071008503194500_B32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"2020071008503194500_B33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood.V124.21.304.304","article-title":"Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM) [abstract]","volume":"124","author":"Lacy","year":"2014","journal-title":"Blood"},{"key":"2020071008503194500_B34","article-title":"Optimismm: phase 3 trial of pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed\/refractory multiple myeloma","author":"Richardson"},{"issue":"20","key":"2020071008503194500_B35","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"2020071008503194500_B36","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma [published online ahead of print 18 Dec 2017]","author":"Krishnan","journal-title":"Leukemia"},{"key":"2020071008503194500_B37","article-title":"Elotuzumab plus pomalidomide\/dexamethasone (epd) versus pd for treatment of relapsed\/refractory multiple myeloma (rrmm): results from the phase 2, randomized open-label eloquent-3 study","author":"Dimopoulos"},{"key":"2020071008503194500_B38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma [abstract]","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020071008503194500_B39","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/24\/2555\/1746880\/blood863829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/24\/2555\/1746880\/blood863829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T12:51:23Z","timestamp":1594385483000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/24\/2555\/39537\/Pomalidomide-cyclophosphamide-and-dexamethasone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-07-863829","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}